BIOLARGO, INC.

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B4 in the pre-IPO sequence.

Price $0.00 · Range $0.00 to $0.00 · 550,000,000 shares · Gross proceeds $370,000

Common Stock · Ticker BLGO · Over-allotment 0 · Use of proceeds debt repayment and working capital

BIOLARGO, INC. is preparing for its IPO, as outlined in the S-1 filing, with a focus on its diversified operations across energy, water, and medical technology sectors. The company's subsidiaries include BioLargo Energy Technologies, Inc. (BETI), Clyra Medical Technologies, Inc., and others, each targeting distinct markets. The filing highlights financial details, including share structures, debt obligations, and revenue streams, while emphasizing risks related to market concentration, liquidity, and regulatory challenges.

2026-04-09 · 0001437749-26-011875

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1 in the pre-IPO sequence.

Price $0.00 · Range $0.00 to $0.00 · 50,000,000 shares · Gross proceeds $33,500

Common Stock · Ticker BLGO · Over-allotment 0 · Use of proceeds Proceeds will be used for general corporate purposes.

BIOLARGO, INC. is preparing for its IPO, as indicated by the S-1 filing. The company's financials include details on common stock, retained earnings, and debt obligations. Subsidiaries like ClyraMedicalTechnologies and BiolargoEnergyTechnologies are mentioned, along with financial metrics such as aggregate intrinsic value and revenue streams. The filing highlights ongoing operations, including equipment, leasehold improvements, and government grants.

2026-04-09 · 0001437749-26-011880

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

BioLargo, Inc. is registering 34,888,449 shares of common stock for sale by selling stockholders, including 30,286,473 shares from warrant exercises at $0.2586 per share and 4,601,976 already issued. The company will not receive proceeds from the sale, but may receive up to $7,969,461 if warrants are fully exercised. The shares are listed on OTCQX with a recent price of $0.205. Selling stockholders may act as underwriters, and the offering involves high risk.

2025-06-11 · 0001437749-25-020012

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. filed a Notice of Effectiveness for its registration statement on June 9, 2025, following a previous 424B4 prospectus dated April 25, 2025. The filing relates to the offer and sale of up to 25,507,789 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder. The company did not receive proceeds from the sale, and the shares are quoted on the OTC Markets under 'BLGO.'

2025-06-09 · 9999999995-25-001867

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

25,507,789 shares

Common · Exchange OTCQX · Ticker BLGO · Selling stockholders only · Use of proceeds The company may receive up to $9,076,580 in additional gross proceeds from sales under the Purchase Agreement. · Underwriters Lincoln Park Capital Fund, LLC

BioLargo, Inc. has filed a prospectus supplement (424B4) relating to the offer and sale of up to 25,507,789 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder. The shares are registered under a prior purchase agreement dated December 13, 2022, with proceeds not benefiting BioLargo. The filing emphasizes the high-risk nature of the investment and outlines the plan of distribution by the selling stockholder, who is also classified as an underwriter.

2025-04-25 · 0001437749-25-013152

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. has received notice of effectiveness for its registration statement, confirming the availability of up to 17,683,826 shares of common stock for sale by selling stockholders. The shares are issuable upon exercise of warrants granted between 2014 and 2019, with expiration dates through 2024. The company emphasizes that it will not receive proceeds from the sale, and the registration statement includes risk factors, capitalization details, and distribution plans for the selling stockholders.

2025-04-24 · 9999999995-25-001220

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

34,888,449 shares · Gross proceeds $9,022,461

Common · Exchange OTCQB · Ticker BLGO · Warrants issued between May 4, 2020, and January 26, 2024, at an average exercise price of $0.2586 · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders, company does not receive any proceeds · Underwriters selling stockholders

BioLargo, Inc. is registering 34,888,449 shares of common stock for sale by selling stockholders, representing the exercise of warrants issued between May 2020 and January 2024 at an average price of $0.2586 per share. The company will not receive proceeds from the sale, but may receive up to $9,022,461 if all warrants are exercised. The shares are listed on the OTCQB marketplace, with a recent closing price of $0.35. The filing highlights significant risks associated with the company's operations and liquidity.

2024-04-25 · 0001437749-24-013162

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

25,507,789 shares

common · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters Lincoln Park Capital Fund, LLC

BIOLARGO, INC. has filed a 424B4 prospectus to register up to 25,507,789 shares of common stock for sale by Lincoln Park Capital Fund, LLC, under a December 2022 purchase agreement. The company is not receiving proceeds from the sale, which will be conducted at market prices or negotiated transactions. This follows a prior 424B4 filing related to warrant exercises, with key differences in share sources and potential proceeds.

2024-04-25 · 0001437749-24-013163

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

17,683,826 shares · Gross proceeds $4,480,957

common stock · Exchange OTCQB · Ticker BLGO · Warrants issued between December 2014 and September 2019 with exercise prices from $0.25 to $0.70, expiring through September 2024 · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters selling stockholders

BioLargo, Inc. is registering 17,683,826 shares of common stock for sale by selling stockholders, representing the remaining warrants exercisable at prices between $0.25 and $0.70 per share. This filing reflects a reduction from the previously registered 26,669,650 shares due to expired warrants. The company does not receive proceeds from the sales, and the selling stockholders may act as underwriters. The filing highlights risks associated with the company's OTCQB listing, warrant expiration, and market volatility.

2024-04-25 · 0001437749-24-013164

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

BioLargo, Inc. has filed a Notice of Effectiveness for its registration statement, enabling the sale of up to 34,888,449 shares of common stock through selling stockholders via warrant exercises. The company is not receiving proceeds from the sale, but potential gross proceeds of $9,022,461 could be generated if warrants are fully exercised. The stock is currently quoted on the OTCQB marketplace under the symbol 'BLGO'. The filing highlights risks associated with the company's operations, including market volatility and reliance on subsidiaries.

2024-04-23 · 9999999995-24-001072

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BIOLARGO, INC. received effectiveness for its filing on April 23, 2024. The filing type (POS AM) and company details remained consistent with the previous submission, though distinct file numbers and accession identifiers differentiate the current and prior records.

2024-04-23 · 9999999995-24-001074

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BiolarGo, Inc. has received effectiveness for its initial public offering (IPO) registration statement on Form S-1, marking the final step in the SEC approval process. The company, previously listed in a post-effective amendment (POS AM) filing, now transitions to a full IPO registration, signaling readiness to offer securities to the public.

2024-04-23 · 9999999995-24-001088

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows RW in the pre-IPO sequence.

34,888,449 shares · Gross proceeds $9,022,461

Common Stock · Exchange OTCQB · Ticker BLGO · Warrants issued between May 4, 2020, and January 26, 2024, exercisable at $0.2586 per share · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders; no issuer proceeds · Underwriters Selling Stockholders

BioLargo, Inc. is registering 34,888,449 shares of common stock for a secondary offering, representing shares issuable upon exercise of warrants issued to selling stockholders between May 2020 and January 2024. The company is not receiving proceeds from the sale, but may receive up to $9,022,461 in gross proceeds if warrants are fully exercised. The filing follows the withdrawal of a prior S-1 registration in April 2023 to incorporate updated information, including its most recent annual report.

2024-04-12 · 0001437749-24-011927

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows 424B4 and ends the active registration process.

BioLargo, Inc. has requested the withdrawal of its previously filed Registration Statement on Form S-1 (File No. 333-271465) to revise the offering and incorporate information from its most recent annual report. The registration was never declared effective, and no securities were issued or sold. The company seeks to refile after addressing regulatory and informational updates.

2024-04-05 · 0001437749-24-011141

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

22,689,035 shares · Gross proceeds $5,684,707

common · Exchange OTCQB · Ticker BLGO · Warrants issued between 2014-2019 with exercise prices from $0.25 to $0.70, expiring 2019-2024 · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders; no issuer proceeds · Underwriters selling stockholders

BioLargo, Inc. is registering 22,689,035 shares of common stock for sale by selling stockholders, representing remaining warrants after expired ones. The company will not receive proceeds, but may gain up to $5.68 million if all warrants are exercised. The stock is quoted on OTCQB with a recent price of $0.2019. The filing updates share counts from a previous registration and details distribution methods.

2023-05-23 · 0001437749-23-015607

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

BioLargo, Inc. filed a Post-Effective Amendment (POS AM) to its S-1 registration statement, confirming the effectiveness of its securities offering as of May 10, 2023. The filing relates to the offer and sale of up to 47,957,601 shares of common stock, including 27,957,601 shares issuable upon warrant exercises and 20,000,000 shares reserved for future warrants. The company emphasizes it will not receive proceeds from the sale but may generate up to $7.1 million from warrant exercises. The offering includes risks related to high volatility, dilution, and limited operating history.

2023-05-10 · 9999999995-23-001357

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B4 in the pre-IPO sequence.

47,957,601 shares

common · Exchange OTCQB · Ticker BLGO · Warrants issued between May 2020 and March 2023 with exercise prices ranging from $0.18 to $0.33, expiring between 6 months and 5 years from issuance · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters selling stockholders

BioLargo, Inc. is registering up to 47,957,601 shares of common stock, primarily from existing and future warrants, with no direct proceeds to the company. The filing expands on previous disclosures (424B4) by detailing warrant expiration dates, potential future warrant issuances, and broader selling stockholder participation. The company remains a shell with no revenue, relying on warrant exercises and private placements.

2023-04-27 · 0001437749-23-011209

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

29,570,000 shares

Common Stock · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters Lincoln Park Capital Fund, LLC

BIOLARGO, INC. filed a prospectus (424B4) for the sale of 29,570,000 shares of common stock by Lincoln Park Capital Fund, LLC. The company is not receiving proceeds from the sale, which is part of a purchase agreement dated December 13, 2022. The shares are listed on the OTCQB marketplace, and the prospectus highlights risks associated with the company's operations, including its status as a shell company and reliance on a single shareholder.

2023-04-24 · 0001437749-23-010910

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. has received SEC approval for its securities offering, with the registration declared effective as of April 19, 2023. The filing references a previous prospectus (424B4) dated January 19, 2023, which outlined the offering of 31,250,000 shares of common stock by Lincoln Park Capital Fund, LLC. The current notice confirms the effectiveness of the registration but does not disclose new material details beyond the prior filing.

2023-04-19 · 9999999995-23-000978

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

31,250,000 shares · Gross proceeds $10,000,000

Common · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Proceeds from the sale of shares by the selling stockholder will go to the selling stockholder, with no proceeds to the company · Underwriters Lincoln Park Capital Fund, LLC

BIOLARGO, INC. has filed a 424B4 prospectus supplement to register 31,250,000 shares of common stock offered by Lincoln Park Capital Fund, LLC. The company will not receive proceeds from the sale, but may receive up to $10M from future sales to Lincoln Park under a separate purchase agreement. The shares are listed on the OTCQB marketplace, with a recent closing price of $0.21. The filing emphasizes the high-risk nature of the investment and outlines the selling stockholder's distribution methods.

2023-01-26 · 0001437749-23-001854

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

BIOLARGO, INC. has received effectiveness for its S-1 registration statement, enabling the offering of up to 31,250,000 shares of common stock via Lincoln Park Capital Fund, LLC. The company will not receive proceeds from the sale, but may receive up to $10M from future sales under a separate purchase agreement. The offering is subject to market conditions and involves significant risks.

2023-01-19 · 9999999995-23-000138

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

31,250,000 shares

common stock · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds No issuer proceeds; proceeds go to selling stockholder · Underwriters Lincoln Park Capital Fund, LLC

BioLargo, Inc. filed an S-1/A amendment to register 31,250,000 shares of common stock offered by Lincoln Park Capital Fund, LLC. The offering relates to a purchase agreement dated December 13, 2022, with proceeds not directly benefiting the company, though potential future gross proceeds up to $10M are noted. The filing updates the prospectus date, stock price, and OTCQB market details.

2023-01-11 · 0001437749-23-000860

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B4 in the pre-IPO sequence.

31,250,000 shares

Common · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Selling stockholders will receive all proceeds from the sale of shares · Underwriters Lincoln Park Capital Fund, LLC

BioLargo, Inc. is registering 31,250,000 shares of common stock under an S-1 filing, offered by Lincoln Park Capital Fund, LLC. The shares are issued under a December 2022 purchase agreement, with sales occurring at market prices or negotiated terms. The company will not receive proceeds from this offering but may receive up to $10M from future sales under the same agreement. Previous 424B4 filing related to warrant exercises, now superseded by this S-1 registration.

2022-12-23 · 0001437749-22-029630

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

36,090,857 shares · Gross proceeds $0.00

common · Exchange OTCQB · Ticker BLGO · Selling stockholders have not exercised warrants to purchase shares registered hereby. · Selling stockholders only · Use of proceeds No issuer proceeds; selling stockholders may use proceeds for general corporate purposes. · Underwriters selling stockholders

BioLargo, Inc. filed a 424B4 prospectus supplement to register up to 36,090,857 shares of common stock for sale by selling stockholders who purchased shares in private placements. The company will not receive proceeds from these sales, and the shares may be sold at negotiated prices, prevailing market prices, or privately negotiated rates. The stock is listed on the OTCQB marketplace, with a recent closing price of $0.234 as of March 30, 2022. The filing emphasizes the high-risk nature of the investment and notes that selling stockholders may be considered underwriters.

2022-04-22 · 0001437749-22-009505

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

4,589,694 shares

Common · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Proceeds from the sale of shares by the selling stockholder will not be received by the company. · Underwriters Lincoln Park Capital Fund, LLC

The current filing relates to the offer and sale of up to 4,589,694 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder. The shares were issued under a March 30, 2020, purchase agreement, with sales occurring at prevailing market prices or through negotiated transactions. The company will not receive proceeds from the sale, though it may receive additional gross proceeds of up to $4,180,000 from future sales under the same agreement. The filing emphasizes the high-risk nature of the securities and notes the company's OTCQB listing.

2022-04-22 · 0001437749-22-009506

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

25,241,369 shares · Gross proceeds $6,801,000

common · Exchange OTCQB · Ticker BLGO · warrants exercisable at $0.25 to $0.70 per share, expiring 2019-2024 · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders; no proceeds to the company · Underwriters selling stockholders

The current filing relates to the offer and sale of up to 25,241,369 shares of common stock by selling stockholders, issuable upon exercise of warrants granted between 2014 and 2019. This replaces a previous filing covering 4,589,694 shares sold by Lincoln Park Capital Fund, LLC. The current filing includes multiple selling stockholders and notes that 1,428,281 warrants have expired since the initial registration, reducing the total shares from 26,669,650 to 25,241,369. The company does not receive proceeds from the sales, and selling stockholders may act as underwriters.

2022-04-22 · 0001437749-22-009507

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. filed a Notice of Effectiveness for its securities registration on April 19, 2022, following a previous 424B4 filing in April 2021. The filing relates to the registration of up to 18,290,084 shares of common stock offered by Lincoln Park Capital Fund, LLC, as a selling stockholder. The company emphasizes it does not receive proceeds from the sale, and the shares were issued under a March 2020 purchase agreement. The filing highlights risks associated with the high volatility of OTCQB-listed securities and the selling stockholder's role as an underwriter.

2022-04-19 · 9999999995-22-001011

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Biolargo, Inc. received effectiveness for its securities registration, indicated by the Notice of Effectiveness dated April 19, 2022. The filing relates to a post-effective amendment (POS AM) under a new file number, suggesting updates to previously filed registration statements.

2022-04-19 · 9999999995-22-001012

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BIOLARGO, INC. received effectiveness for a POS AM filing on April 19, 2022. The filing includes updated administrative details compared to a prior submission, with changes to the file number and accession number.

2022-04-19 · 9999999995-22-001014

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

18,290,084 shares

common stock · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds for working capital and general corporate purposes · Underwriters Lincoln Park Capital Fund, LLC

The prospectus relates to the sale of up to 18,290,084 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder, pursuant to a March 30, 2020 purchase agreement. The company will not receive proceeds from the sale, but may receive up to an additional $6.5 million in gross proceeds from future sales. The shares are registered for resale on the OTCQB marketplace, with risks including market volatility and dilution.

2021-04-13 · 0001437749-21-008754

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

13,801,119 shares

common stock · Exchange OTCQB · Ticker BLGO · Shares may be issued upon exercise of warrants. · Selling stockholders only · Use of proceeds Proceeds will go to the selling stockholders, with no proceeds to the company. · Underwriters Vista Capital Investments, LLC, FirstFire Global Opportunities Fund, LLC, Black Mountain Equities, Inc.

BioLargo, Inc. is registering up to 13,801,119 shares of common stock offered by selling stockholders, including Vista Capital, FirstFire, Black Mountain, and Gemini. The company will not receive proceeds from the sale, which relates to prior transactions and warrant exercises. The filing emphasizes high-risk factors, including liquidity concerns and reliance on future capital raises.

2021-04-12 · 0001437749-21-008739

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

The current filing relates to the registration of up to 26,669,650 shares of common stock issued upon exercise of warrants by selling stockholders. The company is not receiving proceeds from the sale, and the shares are part of a follow-up to prior warrant-related registrations. The filing highlights the expiration of certain warrants and updates the potential gross proceeds from warrant exercises compared to a previous 2020 filing.

2021-04-12 · 0001437749-21-008740

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

36,090,857 shares

common · Exchange OTCQB · Ticker BLGO · Selling stockholders have not exercised warrants to purchase shares. · Selling stockholders only · Use of proceeds Proceeds from the sale will go to the selling stockholders, with no proceeds to the company.

BIOLARGO, INC. filed a 424B4 prospectus on April 12, 2021, relating to the sale of up to 36,090,857 shares of common stock by selling stockholders who purchased shares in private placements. The company does not receive proceeds from these sales, which may occur via public markets, negotiated transactions, or private deals. The shares are registered under a previous registration statement, and selling stockholders may be deemed underwriters. The prospectus highlights risks associated with the OTCQB listing and the company's financial stability.

2021-04-12 · 0001437749-21-008741

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

The current filing confirms the effectiveness of BioLargo, Inc.'s registration statement, allowing selling stockholders (Vista Capital, FirstFire, Black Mountain, Gemini) to offer up to 13,801,119 shares of common stock. The company does not receive proceeds from these sales, which are structured through prior agreements and warrants. The filing emphasizes the high-risk nature of the offering and the company's financial history of losses.

2021-04-08 · 9999999995-21-001338

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BIOLARGO, INC. received effectiveness for a filing on April 8, 2021, with a new file number (333-222572) compared to the previous filing (333-215730). The submission type (POS AM) and company details remained unchanged, suggesting a follow-up or amended filing.

2021-04-08 · 9999999995-21-001340

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BIOLARGO, INC. received SEC effectiveness for its filing on April 8, 2021, with a new file number (333-233534) compared to the previous filing (333-222572). The submission type remains 'POS AM' (Post-Effective Amendment), indicating an updated or amended registration statement. No substantive details about the company's operations, financials, or offering terms are provided in the visible text.

2021-04-08 · 9999999995-21-001345

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BIOLARGO, INC. received effectiveness for its securities offering on April 8, 2021. The filing relates to a revised registration statement (POS AM) compared to the previous submission, with changes primarily reflected in the file number and accession details.

2021-04-08 · 9999999995-21-001348

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Range $0.25 to $0.70 · 26,669,650 shares · Gross proceeds $7,450,000

common · Exchange OTCQB · Ticker BLGO · Warrants issued between December 2014 and September 2019 with exercise prices from $0.25 to $0.70, expiring through 2024 · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the sale of shares · Underwriters selling stockholders

BioLargo, Inc. is registering up to 26,669,650 shares of common stock issuable upon exercise of warrants held by selling stockholders. The warrants, issued between 2014 and 2019, have exercise prices ranging from $0.25 to $0.70 and expire through 2024. The company emphasizes the high-risk nature of the investment, citing liquidity concerns, historical losses, and reliance on future financing. No proceeds will go to BioLargo, but the offering could generate up to $7.45M if warrants are exercised.

2020-04-30 · 0001437749-20-008994

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

36,090,857 shares

common · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds

The current filing is a prospectus for the sale of up to 36,090,857 shares of BioLargo, Inc. common stock by selling stockholders. The shares may be sold at prevailing market prices, negotiated prices, or privately. The company emphasizes that it will not receive proceeds from these sales. The filing highlights risks related to the company's liquidity, going concern status, and reliance on private financings. The shares are listed on the OTCQB marketplace, with a recent last sale price of $0.16.

2020-04-30 · 0001437749-20-009009

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

13,801,119 shares

common stock · Exchange OTCQB · Ticker BLGO · Shares may be issued pursuant to stock purchase warrants · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds, company does not receive any · Underwriters Vista Capital Investments, LLC, FirstFire Global Opportunities Fund, LLC, Black Mountain Equities, Inc.

BioLargo, Inc. is registering up to 13,801,119 shares of common stock for sale by four selling stockholders (Vista Capital, FirstFire, Black Mountain, and Gemini) under a 424B4 filing. The shares originate from prior agreements, including stock purchase warrants and private placements. The company does not receive proceeds from the sales, though it may receive $260,000 if warrants are exercised. The filing highlights significant liquidity challenges, a going concern uncertainty, and reliance on private capital raises. Risk factors emphasize high volatility, lack of profitability, and dependence on external financing.

2020-04-30 · 0001437749-20-009010

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BIOLARGO, INC. received SEC effectiveness for its registration statement on April 28, 2020, following a previous filing on April 21, 2020. The current filing indicates the registration became effective, while the prior submission was a post-effective amendment (POS AM) for an S-1 form.

2020-04-28 · 9999999995-20-000889

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The Notice of Effectiveness indicates that BIOLARGO, INC.'s registration statement became effective on April 28, 2020. The current filing (File Number 333-222572) is a Post-Effective Amendment (POS AM) following a previous filing (File Number 333-215730).

2020-04-28 · 9999999995-20-000891

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BIOLARGO, INC. filed a Post-Effective Amendment (POS AM) to its registration statement, indicating the effectiveness of its IPO filing on April 28, 2020. The amendment suggests updates or corrections to the previously submitted registration statement.

2020-04-28 · 9999999995-20-000895

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows S-1 and confirms the priced prospectus.

44,714,286 shares

Common · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Selling stockholders with no issuer proceeds · Underwriters Lincoln Park Capital Fund, LLC

BIOLARGO, INC. is registering 44,714,286 shares of common stock under a prospectus, with Lincoln Park Capital Fund, LLC acting as the selling stockholder. The shares were issued under a March 2020 purchase agreement, and the company will not receive proceeds from the sale. The offering includes potential additional proceeds of up to $10 million from future sales. The stock is traded on the OTCQB, with a recent closing price of $0.17. The filing highlights significant financial risks, including liquidity concerns and a going-concern uncertainty.

2020-04-21 · 0001437749-20-008126

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. filed a Notice of Effectiveness for its S-1 registration, enabling the sale of 44,714,286 shares of common stock by Lincoln Park Capital Fund, LLC. The previous 424B4 prospectus outlined the same offering, but the current filing confirms the SEC has declared the registration effective. The company is not receiving proceeds from the sale, which is managed by the selling stockholder.

2020-04-21 · 9999999995-20-000812

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B4 in the pre-IPO sequence.

Price $0.20 · 44,714,286 shares · Gross proceeds $8,942,857

Common Stock · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders with no issuer proceeds · Underwriters Lincoln Park Capital Fund, LLC

BioLargo, Inc. is registering 44,714,286 shares of common stock under an S-1 filing, primarily offered by Lincoln Park Capital Fund, LLC. The company is not receiving proceeds from the sale, but previously sold 1,785,715 shares for $250,000 and may receive up to $10 million additional proceeds under a purchase agreement. The filing highlights the company's focus on environmental technology, including clean water and air solutions, with subsidiaries and a minority stake in a wound care company. The company faces liquidity challenges, relying on private offerings and debt restructuring.

2020-04-10 · 0001437749-20-007511

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

17,397,258 shares

common · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters Lincoln Park Capital Fund, LLC

BioLargo, Inc. is registering the offer and sale of up to 17,397,258 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder. The company is not receiving proceeds from the sale, but may receive up to $8.65 million from future sales to Lincoln Park under a purchase agreement. The shares are being sold at market price or through negotiated transactions, with the selling stockholder acting as an underwriter. The offering includes risk factors related to the company's financial instability, negative working capital, and reliance on a single stockholder.

2019-10-02 · 0001437749-19-019399

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Biolargo, Inc. filed a Notice of Effectiveness for its IPO on September 30, 2019, following an earlier S-1 registration statement filed on September 20, 2019. The current filing reflects a post-effective amendment (POS AM) to the initial registration, with updated details including the effectiveness date and file number.

2019-09-30 · 9999999995-19-002203

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows S-1/A and confirms the priced prospectus.

The current 424B4 filing serves as a prospectus for the sale of up to 26,669,650 shares of BioLargo, Inc. common stock by selling stockholders, derived from warrants exercisable between 2014 and 2019. The company does not receive proceeds from the sale, but may generate up to $7.45 million in gross proceeds if all warrants are exercised. The offering highlights significant risks, including liquidity challenges, negative cash flow, and the company's reliance on warrant exercises for capital. The shares are subject to high risk, with the company noting a working capital deficit and ongoing operational losses.

2019-09-20 · 0001437749-19-018822

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. filed an S-1 registration statement, effective September 20, 2019, allowing the sale of up to 26,669,650 shares of common stock by selling stockholders. The shares are issuable upon exercise of warrants granted between December 2014 and September 2019, with exercise prices ranging from $0.25 to $0.70. The company does not receive proceeds from these sales, which may involve selling stockholders acting as underwriters. The filing highlights risks associated with the high volatility of the OTC Markets and the company's historical financial losses.

2019-09-20 · 9999999995-19-002141

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B4 filing.

Price $0.28 · 26,669,650 shares · Gross proceeds $7,449,204

Shares of Common Stock, par value $0.00067 per share · Exchange OTCQB · Ticker BLGO · Warrants exercisable at $0.25 to $0.70 per share, expiring 2019-2024 · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the sale of shares · Underwriters Selling Stockholders

BioLargo, Inc. is registering 26,669,650 shares of common stock for sale by selling stockholders, representing a decrease from the previous 424B4 filing which referenced 36,090,857 shares. The current S-1/A provides updated financial disclosures, including consolidated cash flow statements and detailed notes, while emphasizing risks related to the company's history of losses, dependence on key products, and potential dilution from warrant exercises.

2019-09-17 · 0001437749-19-018540

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

36,090,857 shares

common stock · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds

BioLargo, Inc. is registering up to 36,090,857 shares of common stock for sale by selling stockholders, who may sell the shares on the OTCQB marketplace or through negotiated transactions. The company will not receive proceeds from these sales, and the offering includes risks such as high volatility, lack of liquidity, and historical net losses. The shares were last quoted at $0.235 as of September 12, 2019.

2019-09-13 · 0001437749-19-018339

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

BioLargo, Inc. filed a Notice of Effectiveness for its registration statement on Form S-1, effective September 11, 2019. The filing registers up to 26,118,179 shares of common stock from warrant exercises, with the company not receiving proceeds. The shares are to be sold by selling stockholders, and the prospectus highlights significant risks associated with the investment.

2019-09-11 · 9999999995-19-002058

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B4 in the pre-IPO sequence.

Price $0.28 · 26,118,179 shares · Gross proceeds $7,311,336

Common Stock · Exchange OTCQB · Ticker BLGO · Warrants exercisable at $0.25 to $0.70 per share, expiring 2019-2024 · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders; company does not receive proceeds

BioLargo, Inc. is offering up to 26,118,179 shares of common stock through selling stockholders, representing exercisable warrants issued between 2014 and 2019. The offering includes multiple selling stockholders, with the company not receiving proceeds. The filing highlights the company's focus on sustainable technology and environmental engineering, while noting ongoing liquidity challenges and risks associated with its operations.

2019-08-29 · 0001437749-19-017652

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

13,801,119 shares

common · Exchange OTCQB · Ticker BLGO · Shares may be issued upon exercise of warrants · Selling stockholders only · Use of proceeds Selling stockholders are offering shares; no proceeds to the company · Underwriters Vista Capital Investments, LLC, FirstFire Global Opportunities Fund, LLC, Black Mountain Equities, Inc.

BioLargo, Inc. filed a prospectus (424B4) related to the offer and sale of up to 13,801,119 shares of common stock by selling stockholders, including Vista Capital, FirstFire, Black Mountain, and Gemini. The company itself does not receive proceeds from the sale, but may receive up to $820,000 if warrants are exercised. The stock is quoted on OTCQB, with a recent closing price of $0.18. The filing highlights significant liquidity risks, including a working capital deficit and reliance on private capital raises to continue operations.

2019-05-23 · 0001437749-19-010763

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

BIOLARGO, INC. filed a Notice of Effectiveness for its IPO on May 20, 2019, indicating the registration statement became effective. The filing outlines the offering of Units (common stock and Series C Warrants), Pre-funded Units (pre-funded warrants and Series C Warrants), and underlying common stock. The company is quoted on the OTC Markets but faces risks related to market liquidity, Nasdaq listing approval, and uncertain offering prices.

2019-05-20 · 9999999995-19-001151

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

BioLargo, Inc. is offering units consisting of common stock and Series C Warrants, with potential pre-funded units for investors exceeding ownership thresholds. The offering includes underwriter warrants and details on pricing, with an emphasis on compliance with SEC regulations. The S-1/A amendment updates underwriting terms, pricing assumptions, and listing efforts on Nasdaq.

2019-01-28 · 0001437749-19-001440

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B4 in the pre-IPO sequence.

share of common stock and one Series C W arrant to purchase one share · Exchange OTCQB · Ticker BLGO · Each Unit consists of one share of common stock and one Series C Warrant to purchase one share of common stock · Series C Warrants exercisable at $ per share (adjustable) with 5-year term; Pre-funded Warrants exercisable at $0.01 per share · Use of proceeds General corporate purposes · Flags units, warrants

BioLargo, Inc. is conducting an initial public offering (IPO) registering securities including Units (common stock and Series C Warrants), Pre-funded Units (pre-funded warrants and Series C Warrants), and underlying shares. The offering involves underwriting by H.C. Wainwright & Co., with terms including warrants exercisable at 125% of the public price and potential over-allotment options. The company transitions from private placements (as in prior 424B4 filings) to a public offering, emphasizing risk factors related to liquidity, market acceptance, and operational history.

2018-11-06 · 0001437749-18-019698

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

5,349,170 shares

common · Exchange OTCQB · Ticker BLGO · Shares may be issued pursuant to stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, may be used for general corporate purposes · Underwriters Vista Capital Investments, LLC, FirstFire Global Opportunities Fund, LLC, Black Mountain Equities, Inc.

BIOLARGO, INC. is registering up to 5,349,170 shares of common stock offered by selling stockholders, including Vista Capital, FirstFire, Black Mountain, and Gemini. The company will not receive proceeds from the sale, which may involve warrants and convertible notes. The filing highlights significant risks, including negative working capital, accumulated deficits, and uncertainty about continued operations.

2018-09-10 · 0001437749-18-016819

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows 424B4 and confirms the priced prospectus.

36,090,857 shares

common · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters selling stockholders

The current 424B4 filing by BIOLARGO, INC. relates to the sale of up to 36,090,857 shares of common stock by selling stockholders, who may sell shares on the OTCQB marketplace at prevailing market prices or through negotiated transactions. The company will not receive proceeds from these sales. The filing emphasizes the high-risk nature of the investment, including liquidity concerns and the company's history of losses.

2018-09-10 · 0001437749-18-016823

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. filed a Notice of Effectiveness for its securities offering on September 6, 2018. The filing relates to the sale of up to 19,253,472 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder. The company is not receiving proceeds from the sale, but may receive up to $9,108,112 in gross proceeds from future sales under a purchase agreement. The company faces liquidity challenges, with negative working capital and cumulative deficits, raising concerns about its ability to continue as a going concern.

2018-09-06 · 9999999995-18-002284

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

BIOLARGO, INC. received effectiveness for a post-effective amendment (POS AM) to its securities registration on September 6, 2018. The filing updates previous disclosures but lacks detailed content beyond standard regulatory headers and formatting.

2018-09-06 · 9999999995-18-002286

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

19,253,472 shares

Common · Exchange OTC Markets · Ticker BLGO · Selling stockholders only · Use of proceeds selling stockholders · Underwriters Lincoln Park Capital Fund, LLC

Biolargo, Inc. filed a prospectus (424B4) related to the offer and sale of up to 19,253,472 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder. The company will not receive proceeds from this offering but may receive up to $9.1 million from future sales under a purchase agreement. The filing highlights risks including liquidity challenges, negative working capital, and dependence on raising capital for operations.

2018-08-28 · 0001437749-18-016218

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. received SEC approval for its registration statement, effective June 29, 2018, allowing the company to proceed with the offering of up to 4,319,883 shares of common stock by selling stockholders. The previous filing (424B4) outlined the terms of the offering, including shares issued under purchase agreements and warrants, with no proceeds going to the company. The current filing confirms the effectiveness of the registration but does not disclose new material details beyond the effectiveness date.

2018-06-29 · 9999999995-18-001665

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

4,319,883 shares

common stock · Exchange OTCQB · Ticker BLGO · Warrants issued in 2016 and 2017 may be exercised, potentially generating up to $820,000 in gross proceeds. · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the sale. · Underwriters Vista Capital Investments, LLC, FirstFire Global Opportunities Fund, LLC, Black Mountain Equities, Inc.

BIOLARGO, INC. is registering the sale of 4,319,883 shares of common stock by selling stockholders, including Vista Capital, FirstFire, Black Mountain, and Gemini. The company will not receive proceeds from the sale, and the offering involves significant risks, including historical losses, negative working capital, and dependence on raising capital. The prospectus highlights the company's financial challenges and the high-risk nature of the investment.

2018-02-09 · 0001437749-18-002147

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.41 · 4,319,883 shares · Gross proceeds $1,771,132

Common Stock · Exchange OTCQB · Ticker BLGO · Warrants issued under Securities Purchase Agreements · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the sale of shares · Underwriters Vista Capital Investments, LLC, FirstFire Global Opportunities Fund, LLC, Black Mountain Equities, Inc.

BioLargo, Inc. is registering 4,319,883 shares of common stock for sale by selling stockholders, including Vista Capital, FirstFire, Black Mountain, and Gemini. The company will not receive proceeds from the sale, but may receive up to $820,000 if warrants are exercised. The filing highlights significant financial challenges, including substantial losses and negative working capital, with risks related to liquidity and continued operations.

2018-02-08 · 0001437749-18-002055

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

BIOLARGO, INC. filed a Notice of Effectiveness for its S-1 registration statement on February 8, 2018, declaring the registration of 4,319,883 shares of common stock offered by selling stockholders. The company itself is not selling shares or receiving proceeds, with the offering led by Vista Capital, FirstFire, Black Mountain, and Gemini. The filing highlights risks including financial losses, lack of revenue, and dependence on third-party agreements.

2018-02-08 · 9999999995-18-000377

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

BioLargo, Inc. is offering up to 4,319,883 shares of common stock through selling stockholders, including Vista Capital, FirstFire, Black Mountain, and Gemini. The company does not receive proceeds from the offering, which is registered under Form S-1/A. The filing highlights risks related to the company's history of losses, negative working capital, and dependence on raising capital to sustain operations. The prospectus includes financial data, risk factors, and details about the plan of distribution.

2018-02-07 · 0001437749-18-001916

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $0.41 · 4,117,833 shares · Gross proceeds $1,688,312

Common · Exchange OTCQB · Ticker BLGO · Up to $820,000 in proceeds from warrant exercises · Selling stockholders only · Use of proceeds Proceeds will be used for general corporate purposes, with up to $820,000 from warrant exercises · Flags self_underwritten

BioLargo, Inc. is registering 4,117,833 shares of common stock for sale by selling stockholders, including Vista Capital, FirstFire, Black Mountain, and Gemini. The company will not receive proceeds from the offering, but may receive up to $820,000 if warrants are exercised. The filing highlights significant financial challenges, including cumulative losses, negative working capital, and reliance on external financing. The company operates in water technology, environmental solutions, and medical devices, with risks related to liquidity, dilution, and regulatory approvals.

2018-01-17 · 0001437749-18-000693

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows S-1 and confirms the priced prospectus.

21,977,996 shares

Common Stock · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Proceeds from the offering will be received by the selling stockholder, with no proceeds to the company · Underwriters Lincoln Park Capital Fund, LLC

The current 424B4 filing relates to the sale of up to 21,977,996 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder. The company does not receive proceeds from the sale but may receive up to $10 million in aggregate gross proceeds from sales to Lincoln Park under a Purchase Agreement. The shares are being offered at prevailing market prices or through negotiated transactions, with Lincoln Park acting as an underwriter.

2017-09-22 · 0001437749-17-016260

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BIOLARGO, INC. filed an S-1 registration statement effective September 22, 2017, relating to the offer and sale of up to 21,977,996 shares of common stock by Lincoln Park Capital Fund, LLC. The company is not receiving proceeds from the sale, which is structured as a private placement under Rule 424(b)(4). The filing includes detailed financial statements showing significant losses, negative working capital, and liquidity concerns, with a going concern uncertainty. The company relies on external capital raises and faces risks related to its ability to commercialize technologies and meet obligations.

2017-09-22 · 9999999995-17-002443

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $0.46 · Range $0.46 to $0.46 · 21,977,996 shares · Gross proceeds $10,000,000

Common · Ticker BLGO · Selling stockholders only · Use of proceeds Proceeds go to selling stockholder; company may receive up to $10 million from future sales · Underwriters Lincoln Park Capital Fund, LLC

BioLargo, Inc. is offering up to 21,977,996 shares of common stock through Lincoln Park Capital Fund, LLC, with the company not receiving proceeds from the sale. The prospectus outlines the terms of the offering, including the selling stockholder's ability to sell shares at market prices or through negotiated transactions. The company anticipates potential gross proceeds of up to $10 million from future sales to Lincoln Park under a separate purchase agreement.

2017-09-15 · 0001437749-17-015985

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows S-1/A and confirms the priced prospectus.

BioLargo, Inc. is registering 36,090,857 shares of common stock for resale by selling stockholders who purchased shares in private placements. The company will not receive proceeds from these sales, which may be sold on the OTCQB marketplace at market prices, negotiated prices, or privately. The offering includes risk factors related to the company's financial instability, reliance on capital raises, and uncertainty about its ability to continue as a going concern.

2017-06-15 · 0001437749-17-011341

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

BioLargo, Inc. filed an S-1 registration statement, which became effective on June 15, 2017, allowing the sale of up to 36,090,857 shares of common stock by selling stockholders. The offering relates to private placements, with shares sold on the OTCQB marketplace. The company emphasizes risks associated with its high-risk securities, going concern status, and reliance on raising capital for operations.

2017-06-15 · 9999999995-17-001538

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.50 · 36,090,857 shares · Gross proceeds $15,648,996

Common Stock · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds No proceeds to the company; selling stockholders are selling shares

BioLargo, Inc. is registering up to 36,090,857 shares of common stock for sale by selling stockholders. The offering involves significant risks, including the company's history of losses, lack of profitability, and uncertainty about its ability to continue as a going concern. The company has not received proceeds from previous sales and relies on private placements and debt financing. The prospectus highlights financial challenges, including negative cash flow and high debt levels.

2017-06-09 · 0001437749-17-011081

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.50 · 36,090,857 shares · Gross proceeds $15,648,996

Common Stock · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Selling stockholders will sell the shares, and the company will not receive proceeds

BioLargo, Inc. is offering up to 36,090,857 shares of common stock through selling stockholders, primarily from private placements. The company operates in multiple sectors, including water technology and medical devices, but faces significant financial challenges, including substantial losses, negative cash flow, and uncertainty about its ability to continue as a going concern. The offering involves high risks, and the company relies on raising capital to sustain operations.

2017-06-05 · 0001437749-17-010648

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.50 · 36,090,857 shares · Gross proceeds $15,648,996

Shares of Common Stock, par value $0.00067 per share, to be sold by Selling Stockholders · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Proceeds from the sale of shares by selling stockholders will not be received by the company

BioLargo, Inc. is registering 36,090,857 shares of common stock for sale by selling stockholders, with no proceeds going to the company. The offering involves significant risks, including the company's history of operating losses, negative cash flow, and uncertainty about its ability to continue as a going concern. The prospectus highlights financial challenges, including an accumulated deficit of $93.9 million as of March 31, 2017, and reliance on raising additional capital to sustain operations.

2017-05-23 · 0001437749-17-009928

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.50 · 36,090,857 shares · Gross proceeds $15,648,996

Shares of Common Stock, par value $0.00067 per share, to be sold by Selling Stockholders · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Selling stockholders will sell shares, issuer does not receive proceeds · Underwriters Selling Stockholders

BioLargo, Inc. is offering up to 36,090,857 shares of common stock through selling stockholders, with no proceeds going to the company. The filing highlights the company's history of losses, negative working capital, and substantial doubt about its ability to continue as a going concern. The company relies on raising capital to fund operations and has not generated sufficient revenue to sustain itself. The offering involves significant risks, including the lack of guaranteed proceeds and the volatility of the OTCQB market.

2017-05-01 · 0001437749-17-007648

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Range $0.25 to $0.78 · 36,090,857 shares

Shares of Common Stock, par value $0.00067 per share · Exchange OTCQB · Ticker BLGO · Selling stockholders only · Use of proceeds Selling stockholders will receive all proceeds from the offering

BioLargo, Inc. filed an S-1/A registration statement to amend its initial S-1 filing, focusing on updating details related to the registration of 36,090,857 shares of common stock. The amendment includes updated financial disclosures, registration fee calculations, and additional details on the company's capital structure, including shares issuable upon conversion of convertible notes and exercise of warrants. The filing emphasizes the company's financial challenges, including significant losses and reliance on future capital raises.

2017-03-30 · 0001437749-17-005640

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

First tracked pre-IPO filing for this issuer.

Range $0.25 to $0.75 · 36,003,708 shares · Gross proceeds $14,398,978

Common Stock · Exchange OTCQB · Ticker BLGO · Warrants exercisable at $0.40-$0.75 · Use of proceeds Use of proceeds from primary offering will be for working capital and general corporate purposes

BioLargo, Inc. is registering 36,003,708 shares of common stock for resale by selling stockholders, including shares from convertible notes, warrants, and prior conversions. The company operates in biotechnology with subsidiaries focused on water treatment, medical technologies, and environmental solutions. The filing highlights risks related to liquidity, lack of profitability, and reliance on capital raises.

2017-01-25 · 0001437749-17-001105

Filing Timeline

2 comparable deals

Recent News